[go: up one dir, main page]

WO2008115470A3 - Hox-gene expression as a biomarker for igf-1r therapeutics - Google Patents

Hox-gene expression as a biomarker for igf-1r therapeutics Download PDF

Info

Publication number
WO2008115470A3
WO2008115470A3 PCT/US2008/003494 US2008003494W WO2008115470A3 WO 2008115470 A3 WO2008115470 A3 WO 2008115470A3 US 2008003494 W US2008003494 W US 2008003494W WO 2008115470 A3 WO2008115470 A3 WO 2008115470A3
Authority
WO
WIPO (PCT)
Prior art keywords
igf
tumor
hox
subject
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/003494
Other languages
French (fr)
Other versions
WO2008115470A2 (en
Inventor
Fred Edmond Bertrand Iii
Jarrett Thomas Whelan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East Carolina University
Original Assignee
East Carolina University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East Carolina University filed Critical East Carolina University
Publication of WO2008115470A2 publication Critical patent/WO2008115470A2/en
Publication of WO2008115470A3 publication Critical patent/WO2008115470A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention provides methods for treating or preventing the onset of a tumor in a subject, wherein the tumor is determined to overexpress a Hox gene, including administering to the subject a therapeutically or prophylactically effective amount of an insulin-like growth factor-1 receptor (IGF-1R) antagonist. The invention also provides methods for determining whether a tumor in a subject is amenable to treatment with an IGF-1R antagonist including determining whether the tumor overexpresses a Hox gene, wherein overexpression of the Hox gene indicates that the tumor is amenable to treatment with an IGF-1R inhibitor.
PCT/US2008/003494 2007-03-16 2008-03-17 Hox-gene expression as a biomarker for igf-1r therapeutics Ceased WO2008115470A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91859307P 2007-03-16 2007-03-16
US60/918,593 2007-03-16

Publications (2)

Publication Number Publication Date
WO2008115470A2 WO2008115470A2 (en) 2008-09-25
WO2008115470A3 true WO2008115470A3 (en) 2008-11-20

Family

ID=39766665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003494 Ceased WO2008115470A2 (en) 2007-03-16 2008-03-17 Hox-gene expression as a biomarker for igf-1r therapeutics

Country Status (1)

Country Link
WO (1) WO2008115470A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090368A1 (en) 2007-06-19 2009-04-28 Boehringer Ingelheim Int ANTI-IGF ANTIBODIES
JP2010540960A (en) 2007-10-03 2010-12-24 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Biological marker predicting anticancer response to insulin-like growth factor-1 receptor kinase inhibitor
JP2011501660A (en) 2007-10-03 2011-01-13 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Biological marker predicting anticancer response to insulin-like growth factor-1 receptor kinase inhibitor
EP3064219A3 (en) 2008-12-12 2016-09-28 Boehringer Ingelheim International GmbH Anti-igf antibodies
MX2013008833A (en) 2011-02-02 2013-12-06 Amgen Inc Methods and compositons relating to inhibition of igf-1r.
US9062308B2 (en) 2011-03-01 2015-06-23 The Johns Hopkins University Compositions and methods for treatment of tamoxifen resistant breast cancer
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
CN114295839B (en) * 2021-08-11 2024-06-07 首都医科大学附属北京地坛医院 Application of HOXB7 protein in preparation of kit for identifying oligodendroglioma and astrocytoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071891A (en) * 1996-11-22 2000-06-06 Regents Of The University Of Minnesota Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071891A (en) * 1996-11-22 2000-06-06 Regents Of The University Of Minnesota Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERRANDO ET AL.: "Gene expression signatures in Mll-rearranged T-lineage and B-precursor acture leukemias: dominance of HOX dysregulation.", NEOPLASIA., vol. 102, no. 1, 1 July 2003 (2003-07-01), pages 262 - 268, XP009077442 *
GOLUB ET AL.: "Molecular Classification of Cancer: Class Discovry and Class Prediction by Gene Expression Monitoring.", SCIENCE, vol. 286, 15 October 1999 (1999-10-15), pages 531 - 537, XP002207658 *

Also Published As

Publication number Publication date
WO2008115470A2 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2008115470A3 (en) Hox-gene expression as a biomarker for igf-1r therapeutics
MX2010005768A (en) Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition.
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2009126310A3 (en) Methods for identification and use of agents targeting cancer stem cells
WO2009134487A3 (en) Optimized methods for delivery of dsrna targeting the pcsk9 gene
WO2010048123A3 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AP2011005956A0 (en) Methods of treatment for solid tumors.
MX2009004984A (en) Methods for preserving renal function using xanthine oxidoreductase inhibitors.
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
WO2011127202A3 (en) Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
WO2009045356A3 (en) Microrna compositions in the treatment of vegf-mediated disorders
WO2007149427A3 (en) Tyrosine kinase inhibitors
MX2012009030A (en) Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors.
TN2011000293A1 (en) Protein kinase inhibitors
AU2009270856A8 (en) Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
WO2012116317A3 (en) Combination therapies comprising anti-erbb3 agents
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2010102195A3 (en) Annexin a11 and associated genes as biomarkers for cancer
WO2011146568A8 (en) Predicting response to a her inhibitor
WO2009013621A3 (en) Antibodies and sirna against growth hormone, prolactin and proliferin for use in the treatment of tumors and endometriosis
EP2391372A4 (en) Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition
WO2011034775A3 (en) Methods for treating brain tumors
WO2009013614A3 (en) Marker gene
WO2011122859A3 (en) Composition for predicting chance of brain tumor recurrence and survival prognosis, and kit containing same
WO2006101761A3 (en) Mitotic kinesin inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08726904

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08726904

Country of ref document: EP

Kind code of ref document: A2